PDCD1 and neoplasm: A recent study showed that treatment with another anti-PD-1 humanised IgG4 antibody lambrolizumab in patients with advanced melanoma led to a tumour regression response rate of 38% (according to the response evaluation criteria in solid tumours, RECIST), with a durable effect and a median progression-free survival >7 months.